(CercleFinance.com) – The biopharmaceutical company Lysogene announces that it has entered into a € 15 million loan agreement with the European Investment Bank (EIB) to accelerate the development of its gene therapy platform.
This funding will support the clinical development of its main drug candidates, including the phase 1/2 clinical trial with LYS-GM101 in GM1 gangliosidosis, and the launch of preclinical studies with LYS-FXS01 in fragile X syndrome. .
Lysogene will receive the EIB loan in three tranches, namely a first tranche of three million euros that can be drawn unconditionally, and two others of respectively five and seven million available upon reaching predefined milestones.